The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.
Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system.
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
The National Eye Institute (NEI) seek research co-development or licensees for advancing AAV8/9-based therapies for X-linked forms of retinitis pigmentosa (XLRP) caused by mutations in RPGR (retinitis pigmentosa GTPase regulator) or RP2 (retinitis pigmentosa 2) gene.
The National Cancer Institute (NCI) seeks research licensees for a process that reduces nucleic acid (RNA and DNA) degradation and improves protein integrity in tissue preserved as fixed paraffin embedded specimens.
Researchers at the National Eye Institute have developed a new cytokine therapy that delivers functional interleukin 34 (IL-34) to the retina for treating ocular inflammatory diseases – such as uveitis and degenerative retinal diseases. Intraocular delivery of IL-34 protein or IL-34 gene expression system can effectively prevent retinal inflammation. Thus, it may be a promising strategy to produce long-lasting effects in suppressing abnormal retinal inflammation and preventing photoreceptor death.
The National Eye Institute (NEI) Laboratory of Retinal Cell and Molecular Biology is seeking parties interested in licensing use of sterculic acid and its derivatives for the treatment of diseases related to angiogenesis or mediated by 7-ketocholesterol-induced inflammation, in particular, atherosclerosis, age-related macular degeneration, and Alzheimer''s disease.
Researchers at the National Eye Institute (NEI), have developed a cryopreservation and cell recovery system designed specifically for the efficient cryopreservation, transportation and subsequent thawing of monolayers and tissues on a substrate. This closed cryopreservation/defrost system allows for sterility in addition to increased viability, recovery and safety of tissues that can be used for in vitro culture or surgical transplantation.
The National Eye Institute's Ophthalmic Genetics and Visual Function Branch seeks interested parties to co-develop the use of nitisinone (NTBC) for oculocutaneous albinism or as a treatment for increasing pigmentation in the eyes, hair and/or skin of patients.
Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more selective estrogen-receptor modulators (SERMs), which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration (AMD). SERMs exert their specific protection on photoreceptor degeneration likely by inhibiting microglial activation.
Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
To improve the transduction efficiency the inventors at the National Eye Institute (NEI) have developed a novel, non-invasive approach of applying electric current in combination with a gene therapy vector. This minimally invasive strategy significantly improves the transduction efficiency of AAV vectors in the mouse retina. This represents an improved method for restoring high levels of RS1 expression in the retina of X-linked retinoschisis (XLRS) patients. The NEI seeks a licensing and/or co-development partner to commercialize its AAV-RS1 Gene Therapy for XLRS.
The National Eye Institute (NEI) seeks research co-development or licensees for making research- or clinical-grade preservation solutions for cold-sensitive organ transplantation or protection of brain injury or trauma during surgery.
Researchers at the National Cancer Institute (NCI) have developed an engineered storage unit for frozen tissue, that provides a permanent base on which to mount tissue frozen in OCT and an enclosure for storage. The unit provides for chain-of-custody labeling and acts as an insulating container to protect the specimen. Other elements include devices for freezing the tissue to the base, as well as a holder for the base to facilitate cryosectioning. Application of the storage system allows a frozen tissue specimen to be moved between storage and cryosectioning without loss of label, deformation of tissue, or thermal alterations.
Researchers at the National Eye Institute (NEI) developed a surgical tool to place tissue into position in the retina. The NEI seeks co-development or licensing to commercialize a prototype already in pre-manufacturing. Alternative uses will be considered.
The National Eye Institute (NEI) and National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS) seeks licensing and/or co-development of a method of producing human retinal pigment epithelial (RPE) cells from human induced pluripotent stem cells (iPSCs).
Researchers at the National Eye Institute (NEI) have generated Induced Pluripotent Stem Cells (iPS) from two Late-Onset Reginal (L-ORD) patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. All iPS cells were differentiated into authenticated Retinal Pigment Epithelium (RPE) cells. The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration.
Researchers at the National Cancer Institute (NCI) developed a genetic assay for detecting transcription errors in RNA synthesis. This new assay extends the familiar concept of an Ames test which monitors DNA damage and synthesis errors to the previously inaccessible issue of RNA synthesis fidelity. The FDA requires genetic DNA focused tests for all drug approval as it assesses the in vivo mutagenic and carcinogenic potential of a drug. The new assay will open an approach to monitoring the impact of treatments on the accuracy of RNA synthesis. Errors in transcription have been hypothesized to be a component of aging and age-related diseases. The National Cancer Institute (NCI) seeks licensing partners for the genetic assay.